ArticleEuropean heart journal. Cardiovascular pharmacotherapy2018
Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study.
Article in European heart journal. Cardiovascular pharmacotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07151183 (A Prospective Research on Diagnosis, Prognosis, and Mechanisms of Panvascular Disease), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Research on Diagnosis, Prognosis, and Mechanisms of Panvascular Disease
Who cites it
34 citing papers in PubMed, 69 citations in OpenAlex.
- Association Between Fruits and Vegetables Consumption and Premature Coronary Artery Disease (PCAD): A Multi-Center Case Control Study.Food science & nutrition · 2026Article
- Article
- Identification and Analysis of PANoptosis Associated with Coronary Artery Disease Using Integrated Bioinformatics Methods.Iranian journal of biotechnology · 2026Article
- The association of pre-diabetes with significant coronary artery disease and ischemic mitral regurgitation in patients with non-ST-segment elevation acute coronary syndrome.American heart journal plus : cardiology research and practice · 2025Article
- Prognostic value ofInternational journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Predictors of Major Adverse Cardiovascular Events in Stable Patients After ST Elevation Myocardial Infarction.Clinics and practice · 2025Article
- Evaluation of a machine learning-based metabolic marker for coronary artery disease in the UK Biobank.Atherosclerosis · 2025Article
- Endothelial Dysfunction in Acute Myocardial Infarction: A Complex Association With Sleep Health, Traditional Cardiovascular Risk Factors and Prognostic Markers.Clinical cardiology · 2025Article
- Circulating amino acid signature features urea cycle alterations associated with coronary artery disease.Scientific reports · 2024Observational
- New Modifiable Risk Factors Influencing Coronary Artery Disease Severity.International journal of molecular sciences · 2024Review
- Significance of Multiple Lymphocyte-to-C-Reactive Protein Ratios in Predicting Long-Term Major Cardiovascular Adverse Events in Emergency Percutaneous Coronary Intervention Patients with ST-Segment Elevation Myocardial Infarction.Journal of inflammation research · 2024Article
- Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction-Impact on Tailored Lipid-Lowering Therapy at Discharge.Journal of clinical medicine · 2023Article
- Early Addition of Evolocumab to Statin Treatment in Patients with Acute Coronary Syndrome and Multivessel Disease Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2023Article
- Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts.Lancet (London, England) · 2023Article
- Identification of Potential Biomarkers for Coronary Artery Disease Based on Cuproptosis.Cardiovascular therapeutics · 2023Article
- Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction.Pharmacy (Basel, Switzerland) · 2022Article
- Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis.PharmacoEconomics - open · 2022Article
- Construction and validation of molecular subtypes of coronary artery disease based on ferroptosis-related genes.BMC cardiovascular disorders · 2022Article
- Article
- Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis.Cardiology research and practice · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Long-term prognostic impact of coronary artery disease (CAD) severity in stable post-myocardial infarction (MI) patients is not well known. We examined the impact of CAD severity and co-morbidity on the long-term (1 year and beyond) risk of cardiovascular events post-MI. Methods and results: From nationwide administrative and clinical registers, we identified 55 747 MI patients, during 2004-2010, who had not experienced subsequent MI, stroke, or death within 7 days post-discharge. The risk for primary composite endpoint (MI, stroke, or cardiovascular death) was estimated for the first 365 days after MI (index MI) and from day 366 to study completion (stable post-MI population), corresponding to a mean follow-up of 3.6 (2.2) years. Risk was assessed using cumulative incidence, multivariable adjusted logistic regression and Cox proportional-hazards models. The 1-year cumulative incidence for primary endpoint was 20.0% [95% confidence interval (CI), (19.6-20.3)]. Correspondingly, the 4-year cumulative incidence for primary endpoint was 21.0% (95% CI, 20.6-21.4) in patients without events on the first year. In multivariable models with no significant stenosis as reference, CAD severity was the most important risk factor for cardiovascular events the first 365 days [left main stenosis (LMS): odds ratio and 95% CI, 4.37, 3.69-5.17; 3-vessel disease (VD), 4.18, 3.66-4.77; 2-VD, 3.23, 2.81-3.72; 1-VD, 2.12,-1.85-2.43] and remained from day 366 to study completion [LMS: hazard ratio and 95% CI, 1.91, 1.64-2.22; 3-VD, 1.85,1.65-2.07; 2-VD, 1.55, 1.38-1.74; 1-VD, 1.30, 1.16-1.45]. Conclusion: Despite contemporary treatment at baseline, stable post-MI patients' 4-year outcome was similar to 1-year outcome after MI, and CAD severity remained a critical risk factor the first year and thereafter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.